Followed 138 Times Top-Rated Dividend Stocks

NYSE:ABBV

AbbVie (ABBV) Stock Forecast, Price & News

$148.03

-2.98 (-1.97%)

(As of 05/23/2022 04:03 PM ET)

Add

Compare

Today's Range: $147.19
▼
$152.00
50-Day Range: $146.88
▼
$174.96
52-Week Range: $105.56
▼
$175.91

Volume: 6.62 million shs
Average Volume: 7.86 million shs
Market Capitalization: $261.59 billion

P/E Ratio: 21.24
Dividend Yield: 3.73%
Beta: 0.83

30 days | 90 days | 365 days | Advanced Chart

Receive ABBV News and Ratings via Email

Sign-up to receive the latest news and ratings for AbbVie and its competitors with MarketBeat's FREE daily newsletter.

About AbbVie

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

May 16, 2022 | marketbeat.com

Volatile Times Are When AbbVie Shines the Brightest

Even in a slower growth environment, investors who invest in AbbVie (NYSE:ABBV) stock can count on a generous dividend that will add to the stock's total return

May 13, 2022 | marketbeat.com

3 Volatile Stocks that Analysts Love (ABBV)

Investing in high-volatility stocks can help deliver some unexpected gains. However, this doesn’t mean that investors must become experts in market timing. A better way to select high-volatility stocks is by looking for those stocks that are being given a buy rating from analysts. And in this article, we’re giving you three volatile stocks with high upside potential.

May 2, 2022 | pricetargets.com

Wells Fargo Sets New High-Price Target For AbbVie (ABBV)

May 2, 2022 | pricetargets.com

Wells Fargo Sets New High-Price Target For AbbVie

May 23, 2022 | stocknews.com

5 Stalwart Stocks to Load Up on During the Market Sell-Off

May 23, 2022 | finance.yahoo.com

CHMP Recommends European Commission Approval of Upadacitinib (RINVOQ®) for the Treatment of Adults with Moderate to Severe Ulcerative Colitis

May 22, 2022 | americanbankingnews.com

Zacks: Analysts Expect AbbVie Inc. (NYSE:ABBV) to Post $3.44 EPS

May 20, 2022 | benzinga.com

AbbVie Submits FDA Application For Continuous, 24-Hour Infusion Therapy For Parkinson's

May 20, 2022 | americanbankingnews.com

Henry O. Gosebruch Sells 83,960 Shares of AbbVie Inc. (NYSE:ABBV) Stock

May 20, 2022 | americanbankingnews.com

Michael Severino Sells 100,000 Shares of AbbVie Inc. (NYSE:ABBV) Stock

May 19, 2022 | seekingalpha.com

J&J touts Tremfya in-vitro studies differentiating it from AbbVie's Skyrizi (NYSE:JNJ) - Seeking Alpha

May 18, 2022 | marketwatch.com

AbbVie Inc. stock falls Wednesday, still outperforms market - MarketWatch

May 17, 2022 | fool.com

Is It Too Late to Buy AbbVie Stock? - The Motley Fool

See More Headlines

Industry, Sector and Symbol

Stock Exchange: NYSE
Industry: Pharmaceutical preparations
Sub-Industry: Pharmaceuticals
Sector: Medical
Current Symbol: NYSE:ABBV
Previous Symbol
CUSIP: 00287Y10
CIK: 1551152
Web: www.abbvie.com
Phone: (847) 932-7900
Fax: 302-655-5049
Employees: 50,000
Year Founded: 2013

Sales & Book Value

Annual Sales: $56.20 billion
Price / Sales: 4.65
Cash Flow: $17.23 per share
Price / Cash Flow: 8.59
Book Value: $9.23 per share
Price / Book: 16.04

Profitability

EPS (Most Recent Fiscal Year): $6.97
Net Income: $11.54 billion
Net Margins: 22.00%
Pretax Margin: 24.77%
Return on Equity: 159.31%
Return on Assets: 15.73%

Debt

Debt-to-Equity Ratio: 3.89
Current Ratio: 0.82
Quick Ratio: 0.71

Price-To-Earnings

Trailing P/E Ratio: 21.24
Forward P/E Ratio: 10.53
P/E Growth: 4.26

Miscellaneous

Outstanding Shares: 1,767,110,000
Free Float: 1,765,696,000
Market Cap: $261.59 billion
Optionable: Optionable

Company Calendar

Ex-Dividend for 5/16 Dividend: 4/13/2022
Last Earnings: 4/29/2022
Dividend Payable: 5/16/2022
Today: 5/23/2022
Next Earnings (Estimated): 7/29/2022
Fiscal Year End: 12/31/2022

Social Links

MarketRank^™

Overall MarketRank^™

2.78 out of 5 stars

Medical Sector

37th out of 1,416 stocks

Pharmaceutical Preparations Industry

12th out of 677 stocks

2.3 Analyst's Opinion

Consensus Rating
AbbVie has received a consensus rating of Buy. The company's average rating score is 2.56, and is based on 10 buy ratings, 5 hold ratings, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $159.75, AbbVie has a forecasted upside of 8.0% from its current price of $147.96.
Amount of Analyst Coverage
AbbVie has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

4.9 Community Rank

Outperform Votes
AbbVie has received 1,263 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
AbbVie has received 448 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
AbbVie has received 73.82% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about AbbVie and other stocks. Vote “Outperform” if you believe ABBV will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ABBV will underperform the S&P 500 over the long term. You may vote once every thirty days.

4.2 Dividend Strength

Dividend Leadership
AbbVie is a leading dividend payer. It pays a dividend yield of 3.73%, putting its dividend yield in the top 25% of dividend-paying stocks.
Dividend Growth
AbbVie has been increasing its dividend for 50 years.
Dividend Coverage
The dividend payout ratio of AbbVie is 80.92%. Payout ratios above 75% are not desirable because they may not be sustainable.
Dividend Sustainability
Based on earnings estimates, AbbVie will have a dividend payout ratio of 47.76% next year. This indicates that AbbVie will be able to sustain or increase its dividend.

2.5 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, AbbVie insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $74,384,651.00 in company stock.
Percentage Held by Insiders
Only 0.08% of the stock of AbbVie is held by insiders.
Percentage Held by Institutions
67.03% of the stock of AbbVie is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0 Earnings and Valuation

Earnings Growth
Earnings for AbbVie are expected to decrease by -16.00% in the coming year, from $14.06 to $11.81 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of AbbVie is 21.23, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 9.96.
Price to Earnings Ratio vs. Sector
The P/E ratio of AbbVie is 21.23, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 12.45.
Price to Earnings Growth Ratio
AbbVie has a PEG Ratio of 4.26. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
AbbVie has a P/B Ratio of 16.03. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

AbbVie (NYSE:ABBV) Frequently Asked Questions

Is AbbVie a buy right now?: 16 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AbbVie in the last twelve months. There are currently 1 sell rating, 5 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AbbVie stock.
View analyst ratings for AbbVie or view top-rated stocks.
When is AbbVie's next earnings date?: AbbVie is scheduled to release its next quarterly earnings announcement on Friday, July 29th 2022.
View our earnings forecast for AbbVie.
How were AbbVie's earnings last quarter?: AbbVie Inc. (NYSE:ABBV) posted its quarterly earnings results on Friday, April, 29th. The company reported $3.16 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.14 by $0.02. The firm earned $13.36 billion during the quarter, compared to analysts' expectations of $13.61 billion. AbbVie had a trailing twelve-month return on equity of 159.31% and a net margin of 22.00%. The company's revenue was up 2.7% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.95 earnings per share.
View AbbVie's earnings history.
How often does AbbVie pay dividends? What is the dividend yield for AbbVie?: AbbVie declared a quarterly dividend on Thursday, February 17th. Investors of record on Friday, April 15th will be given a dividend of $1.41 per share on Monday, May 16th. This represents a $5.64 annualized dividend and a yield of 3.81%. The ex-dividend date is Wednesday, April 13th.
View AbbVie's dividend history.
Is AbbVie a good dividend stock?: AbbVie pays an annual dividend of $5.64 per share and currently has a dividend yield of 3.73%. AbbVie has been increasing its dividend for 50 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio of AbbVie is 80.92%. Payout ratios above 75% are not desirable because they may not be sustainable. Based on earnings estimates, AbbVie will have a dividend payout ratio of 47.76% next year. This indicates that AbbVie will be able to sustain or increase its dividend.
View AbbVie's dividend history.
What guidance has AbbVie issued on next quarter's earnings?: AbbVie updated its FY 2022 earnings guidance on Monday, May, 9th. The company provided EPS guidance of $13.92-$14.12 for the period, compared to the consensus earnings per share estimate of $14.11. The company issued revenue guidance of $59.40 billion-$59.40 billion, compared to the consensus revenue estimate of $60.04 billion.
What price target have analysts set for ABBV?: 16 equities research analysts have issued 1-year price targets for AbbVie's stock. Their forecasts range from $135.00 to $200.00. On average, they anticipate AbbVie's stock price to reach $159.75 in the next twelve months. This suggests a possible upside of 7.9% from the stock's current price.
View analysts' price targets for AbbVie or view top-rated stocks among Wall Street analysts.
Who are AbbVie's key executives?: AbbVie's management team includes the following people:
Mr. Richard A. Gonzalez, Chairman & CEO (Age 68, Pay $7.42M) (LinkedIn Profile)
Dr. Michael E. Severino M.D., Vice Chairman & Pres (Age 56, Pay $4.29M) (LinkedIn Profile)
Mr. Robert A. Michael, Vice Chairman of Fin. & Commercial Operations and CFO (Age 52, Pay $3.82M) (LinkedIn Profile)
Ms. Laura J. Schumacher, Vice Chairman of External Affairs, Chief Legal Officer & Corp. Sec. (Age 59, Pay $4.18M) (LinkedIn Profile)
Mr. Jeffrey Ryan Stewart, Exec. VP & Chief Commercial Officer (Age 53, Pay $3.25M)
Dr. Azita Saleki-Gerhardt Ph.D., Exec. VP of Operations (Age 59)
Dr. Thomas J. Hudson, Sr. VP of R&D and Chief Scientific Officer (Age 60)
Ms. Elizabeth Shea, VP of Investor Relations
Mr. Timothy J. Richmond, Exec. VP & Chief HR Officer (Age 56) (LinkedIn Profile)
Mr. Henry O. Gosebruch, Exec. VP & Chief Strategy Officer (Age 49) (LinkedIn Profile)
What is Richard A. Gonzalez's approval rating as AbbVie's CEO?: 580 employees have rated AbbVie CEO Richard A. Gonzalez on Glassdoor.com. Richard A. Gonzalez has an approval rating of 88% among AbbVie's employees.
Who are some of AbbVie's key competitors?: Some companies that are related to AbbVie include Johnson & Johnson (JNJ), Pfizer (PFE), Eli Lilly and (LLY), Merck & Co., Inc. (MRK), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Horizon Therapeutics Public (HZNP), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Pacira BioSciences (PCRX), Corcept Therapeutics (CORT), Supernus Pharmaceuticals (SUPN), Nektar Therapeutics (NKTR) and Omeros (OMER).
View all of ABBV's competitors.
What other stocks do shareholders of AbbVie own?: Based on aggregate information from My MarketBeat watchlists, some companies that other AbbVie investors own include Intact Financial (IFC), Constellation Software (CSU), AutoCanada (ACQ), Alimentation Couche-Tard (ATD.B), Vermilion Energy (VET), AT&T (T), Bristol-Myers Squibb (BMY), Wheaton Precious Metals (WPM), Rogers Communications (RCI) and Open Text (OTEX).
What is AbbVie's stock symbol?: AbbVie trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABBV."
Who are AbbVie's major shareholders?: AbbVie's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (8.52%), BlackRock Inc. (7.34%), State Street Corp (4.42%), Capital International Investors (1.73%), Northern Trust Corp (1.28%) and Bank of New York Mellon Corp (1.12%). Company insiders that own AbbVie stock include Brian L Durkin, Carlos Alban, Carrie C Strom, Carrie C Strom, Elaine K Sorg, Henry O Gosebruch, Jeffrey Ryan Stewart, Laura J Schumacher, Michael Severino, Richard A Gonzalez, Robert A Michael, Roxanne S Austin and Timothy J Richmond.
View institutional ownership trends for AbbVie.
Which institutional investors are selling AbbVie stock?: ABBV stock was sold by a variety of institutional investors in the last quarter, including Nomura Holdings Inc., Bank of New York Mellon Corp, State Street Corp, Federated Hermes Inc., abrdn plc, Renaissance Technologies LLC, UBS Group AG, and Capital Research Global Investors. Company insiders that have sold AbbVie company stock in the last year include Brian L Durkin, Carrie C Strom, Elaine K Sorg, Henry O Gosebruch, Jeffrey Ryan Stewart, Laura J Schumacher, Michael Severino, Richard A Gonzalez, Robert A Michael, Roxanne S Austin, and Timothy J Richmond.
View insider buying and selling activity for AbbVie or view top insider-selling stocks.
Which institutional investors are buying AbbVie stock?: ABBV stock was purchased by a variety of institutional investors in the last quarter, including Capital International Investors, Vanguard Group Inc., Arrowstreet Capital Limited Partnership, California Public Employees Retirement System, BlackRock Inc., Swiss National Bank, Robeco Institutional Asset Management B.V., and Caisse DE Depot ET Placement DU Quebec.
View insider buying and selling activity for AbbVie or or view top insider-buying stocks.
How do I buy shares of AbbVie?: Shares of ABBV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is AbbVie's stock price today?: One share of ABBV stock can currently be purchased for approximately $148.03.
How much money does AbbVie make?: AbbVie has a market capitalization of $261.59 billion and generates $56.20 billion in revenue each year. The company earns $11.54 billion in net income (profit) each year or $6.97 on an earnings per share basis.
How many employees does AbbVie have?: AbbVie employs 50,000 workers across the globe.
Does AbbVie have any subsidiaries?: The following companies are subsidiares of AbbVie: AbbVie (Gibraltar) Holdings Limited, AbbVie (Gibraltar) Holdings Limited Luxembourg S.C.S., AbbVie (Gibraltar) Limited, AbbVie (Pty) Ltd., AbbVie A/S, AbbVie AB, AbbVie AG, AbbVie AS, AbbVie Australasia Holdings Limited, AbbVie B.V., AbbVie Bahamas Ltd., AbbVie Biofarmacevtska družba d.o.o., AbbVie Biopharmaceuticals GmbH, AbbVie Biopharmaceuticals LLC, AbbVie Biopharmaceuticals Ltd., AbbVie Bioresearch Center Inc., AbbVie Biotech Ventures Inc., AbbVie Biotechnology GmbH, AbbVie Biotechnology Ltd, AbbVie Biotherapeutics Inc., AbbVie Biotherapeutics Limited, AbbVie Central Finance B.V., AbbVie Corp, AbbVie Corporation, AbbVie Deutschland GmbH & Co. KG, AbbVie EOOD, AbbVie Endocrine Inc., AbbVie Endocrinology Inc., AbbVie Farmacéuticos S.A. de C.V., AbbVie Farmacêutica Ltda., AbbVie Finance B.V., AbbVie Finance Corporation, AbbVie Finance LLC, AbbVie GK, AbbVie GmbH, AbbVie Holdings Corporation, AbbVie Holdings Inc., AbbVie Holdings KK, AbbVie Holdings SAS, AbbVie Holdings Unlimited, AbbVie Holdings s.r.o., AbbVie International S.à r.l., AbbVie Investments Limited, AbbVie Investments S.à r.l., AbbVie Ireland Holdings Limited, AbbVie Ireland NL B.V., AbbVie Ireland Unlimited Company, AbbVie Japan Holdings B.V., AbbVie Kft., AbbVie Komplementär GmbH, AbbVie L.L.C., AbbVie L.da, AbbVie Limited, AbbVie Limited Liability Company, AbbVie Logistics B.V., AbbVie Ltd, AbbVie Ltd., AbbVie Manufacturing Management Limited, AbbVie Nederland Holdings B.V., AbbVie Operations Singapore Pte. Ltd., AbbVie Overseas S.à r.l., AbbVie Oy, AbbVie Participações Ltda., AbbVie Pharmaceutical Trading (Shanghai) Co. Ltd., AbbVie Pharmaceuticals B.V., AbbVie Pharmaceuticals GmbH, AbbVie Pharmaceuticals LLC, AbbVie Pharmaceuticals SCA., AbbVie Pharmaceuticals Societe Anonyme, AbbVie Polska Sp. z o.o., AbbVie Productos Farmacéuticos Limitada, AbbVie Products LLC, AbbVie Promoção L.da, AbbVie Pte. Ltd., AbbVie Pty Ltd, AbbVie Purchasing LLC, AbbVie Real Estate Management GmbH, AbbVie Research B.V., AbbVie Resources Inc., AbbVie Resources International Inc., AbbVie Respiratory LLC, AbbVie S. de R.L., AbbVie S.A., AbbVie S.A., AbbVie S.A.S., AbbVie S.R.L., AbbVie S.r.l., AbbVie S.à r.l., AbbVie SA, AbbVie SAS, AbbVie SIA, AbbVie Sarl, AbbVie Sdn. Bhd., AbbVie Sp. z o.o., AbbVie Spain S.L., AbbVie Stemcentrx LLC, AbbVie Trading S.R.L., AbbVie Trustee Company Limited, AbbVie Tıbbi İlaçlar Sanayi ve Ticaret Limited Şirketi, AbbVie UAB, AbbVie UK Biopharmaceuticals Ltd, AbbVie UK Holdco Limited, AbbVie UK Ltd, AbbVie US Holdings LLC, AbbVie US LLC, AbbVie Venezuela B.V., AbbVie Venezuela Holdings B.V., AbbVie Ventures LLC, AbbVie d.o.o., AbbVie s.r.o., Aeropharm Technology LLC, Allergan, BioDisplay Technologies Inc., Fournier Laboratories Ireland Ltd., Fremont Holding L.L.C., Fundación AbbVie, IEP Pharmaceutical Devices LLC, ImmuVen, KOS Pharmaceuticals Inc., Knoll LLC, Knoll Pharmaceutical Company, Life Properties Inc., Mavupharma, Organics L.L.C., Pharmacyclics (Europe) Limited, Pharmacyclics (Shanghai) Management Consulting Services Limited, Pharmacyclics Cayman Ltd., Pharmacyclics Inc, Pharmacyclics LLC, Pharmacyclics Switzerland GmbH, Rowell Laboratories Inc., S.C. AbbVie S.R.L., Sapphire Merger Sub Inc., Stem CentRx, Stemcentrx Cayman Ltd., Suffolk Merger Sub Inc., and Unimed Pharmaceuticals LLC.
When was AbbVie founded?: AbbVie was founded in 2013.
What is AbbVie's official website?: The official website for AbbVie is www.abbvie.com.
How can I contact AbbVie?: AbbVie's mailing address is 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. The company can be reached via phone at (847) 932-7900 or via fax at 302-655-5049.

This page was last updated on 5/23/2022 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

AbbVie (ABBV) Stock Forecast, Price & News

About AbbVie

Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous

Company Calendar

Social Links

MarketRank™

Overall MarketRank™

2.3 Analyst's Opinion

4.9 Community Rank

Outperform Votes

Underperform Votes

Community Sentiment

4.2 Dividend Strength

2.5 Company Ownership

0.0 Earnings and Valuation

AbbVie (NYSE:ABBV) Frequently Asked Questions

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources

MarketRank^™

Overall MarketRank^™